Log in | Register

Cholestatic liver (dys)function during sepsis and other critical illnesses

Marc Jenniskens| Lies Langouche| Yoo-Mee Vanwijngaerden| Dieter Mesotten| Greet Van den Berghe
Review
Volume 42, Issue 1 / January , 2016

Pages 16 - 27

Abstract

Objective

In ICU patients, abnormal liver tests are common. Markers of cholestasis are associated with adverse outcome. Research has focused on the possibility that mild hyperbilirubinemia, instead of indicating inadvertent cholestasis, may be adaptive and beneficial. These new insights are reviewed and integrated in the state-of-the-art knowledge on hepatobiliary alterations during sepsis and other critical illnesses.

Data sources

Relevant publications were searched in Medline with search terms bile, bile acids, cholestasis, critical illness, intensive care, sepsis, alone or in combination.

Data synthesis

Studies have shown that bilirubin, but also bile acids, the main active constitutes of bile, are increased in plasma of patients with critical illnesses. In particular the conjugated fractions of bilirubin and bile acids are high, indicating that during critical illness the liver is capable of converting these molecules to less toxic forms. In human liver biopsies of prolonged critically ill patients, expression of bile acid excretion pumps towards the bile canaliculi was lower, while alternative transporters towards the systemic circulation were upregulated. Remarkably, in the presence of increased circulating bile acids, expression of enzymes controlling synthesis of bile acids was not suppressed. This suggested loss of feedback inhibition of bile acids synthesis, possibly explained by the observed cytoplasmic retention of the nuclear FXR/RXR heterodimer. As macronutrient restriction during acute critical illness, an intervention that improved outcome, was found to further increase plasma bilirubin while reducing other markers of cholestasis, a potentially protective role of hyperbilirubinemia was suggested.

Conclusion

The increase in circulating levels of conjugated bile acids and bilirubin in response to acute sepsis/critical illnesses may not necessarily point to cholestasis as a pathophysiological entity. Instead it may be the result of an adaptively altered bile acid production and transport back towards the systemic circulation. How these changes could be beneficial for survival should be further investigated.

Keywords

References

  1. Nesseler N, Launey Y, Aninat C, Morel F, Mallédant Y, Seguin P (2012) Clinical review: the liver in sepsis. Crit Care 16:235
    • View reference on publisher's website
    • View reference on PubMed
  2. Kramer L, Jordan B, Druml W, Bauer P, Metnitz PGH, Austrian Epidemiologic Study on Intensive Care ASDI Study Group (2007) Incidence and prognosis of early hepatic dysfunction in critically ill patients—a prospective multicenter study. Crit Care Med 35:1099–1104
    • View reference on publisher's website
    • View reference on PubMed
  3. Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Schöniger-Hekele M, Madl C, Schenk P (2011) Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med 37:1302–1310
  4. Thomson SJ, Cowan ML, Johnston I, Musa S, Grounds M, Rahman TM (2009) ‘Liver function tests’ on the intensive care unit: a prospective, observational study. Intensive Care Med 35:1406–1411
  5. Horvatits T, Trauner M, Fuhrmann V (2013) Hypoxic liver injury and cholestasis in critically ill patients. Curr Opin Crit Care 19:128–132
    • View reference on publisher's website
    • View reference on PubMed
  6. Henrion J (2012) Hypoxic hepatitis. Liver Int 32:1039–1052
    • View reference on publisher's website
    • View reference on PubMed
  7. Brienza N, Dalfino L, Cinnella G, Diele C, Bruno F, Fiore T (2006) Jaundice in critical illness: promoting factors of a concealed reality. Intensive Care Med 32:267–274
  8. Harbrecht BG, Zenati MS, Doyle HR, McMichael J, Townsend RN, Clancy KD, Peitzman AB (2002) Hepatic dysfunction increases length of stay and risk of death after injury. J Trauma 53:517–523
    • View reference on publisher's website
    • View reference on PubMed
  9. Mesotten D, Wauters J, Van den Berghe G, Wouters PJ, Milants I, Wilmer A (2009) The effect of strict blood glucose control on biliary sludge and cholestasis in critically ill patients. J Clin Endocrinol Metab 94:2345–2352
    • View reference on publisher's website
    • View reference on PubMed
  10. van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA (2010) Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 16:84–90
    • View reference on publisher's website
    • View reference on PubMed
  11. Boland GW, Slater G, Lu DS, Eisenberg P, Lee MJ, Mueller PR (2000) Prevalence and significance of gallbladder abnormalities seen on sonography in intensive care unit patients. AJR Am J Roentgenol 174:973–977
    • View reference on publisher's website
    • View reference on PubMed
  12. Murray FE, Stinchcombe SJ, Hawkey CJ (1992) Development of biliary sludge in patients on intensive care unit: results of a prospective ultrasonographic study. Gut 33:1123–1125
    • View reference on publisher's website
    • View reference on PubMed
  13. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710
  14. Trauner M, Fickert P, Stauber RE (1999) Inflammation-induced cholestasis. J Gastroenterol Hepatol 14:946–959
    • View reference on publisher's website
    • View reference on PubMed
  15. Grau T, Bonet A, Rubio M, Mateo D, Farré M, Acosta JA, Blesa A, Montejo JC, de Lorenzo AG, Mesejo A, Working Group on Nutrition and Metabolism of the Spanish Society of Critical Care (2007) Liver dysfunction associated with artificial nutrition in critically ill patients. Crit Care 11:R10
    • View reference on publisher's website
    • View reference on PubMed
  16. Lat I, Foster DR, Erstad B (2010) Drug-induced acute liver failure and gastrointestinal complications. Crit Care Med 38:S175–S187
    • View reference on publisher's website
    • View reference on PubMed
  17. Porez G, Prawitt J, Gross B, Staels B (2012) Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 53:1723–1737
    • View reference on publisher's website
    • View reference on PubMed
  18. Chiang JYL (2009) Bile acids: regulation of synthesis. J Lipid Res 50:1955–1966
    • View reference on publisher's website
    • View reference on PubMed
  19. Kubitz R, Droge C, Stindt J, Weissenberger K, Haussinger D (2012) The bile salt export pump (BSEP) in health and disease. Clin Res Hepatol Gastroenterol 36:536–553
    • View reference on publisher's website
    • View reference on PubMed
  20. Alrefai WA, Gill RK (2007) Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 24:1803–1823
    • View reference on publisher's website
    • View reference on PubMed
  21. Soroka CJ, Lee JM, Azzaroli F, Boyer JL (2001) Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33:783–791
    • View reference on publisher's website
    • View reference on PubMed
  22. Denk GU, Soroka CJ, Takeyama Y, Chen W-S, Schuetz JD, Boyer JL (2004) Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 40:585–591
    • View reference on publisher's website
    • View reference on PubMed
  23. Lee J, Azzaroli F, Wang L, Soroka CJ, Gigliozzi A, Setchell KD, Kramer W, Boyer JL (2001) Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 121:1473–1484
    • View reference on publisher's website
    • View reference on PubMed
  24. Glass CK, Ogawa S (2006) Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6:44–55
    • View reference on publisher's website
    • View reference on PubMed
  25. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6:517–526
    • View reference on publisher's website
    • View reference on PubMed
  26. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6:507–515
    • View reference on publisher's website
    • View reference on PubMed
  27. Tirona RG, Kim RB (2005) Nuclear receptors and drug disposition gene regulation. J Pharm Sci 94:1169–1186
    • View reference on publisher's website
    • View reference on PubMed
  28. Chiang JYL (2003) Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am J Physiol Gastrointest Liver Physiol 284:G349–G356
    • View reference on publisher's website
    • View reference on PubMed
  29. Halilbasic E, Baghdasaryan A, Trauner M (2013) Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis 17:161–189
    • View reference on publisher's website
    • View reference on PubMed
  30. Glicksman C, Pournaras DJ, Wright M, Roberts R, Mahon D, Welbourn R, Sherwood R, Alaghband-Zadeh J, le Roux CW (2010) Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem 47:482–484
    • View reference on publisher's website
    • View reference on PubMed
  31. Ma K, Xiao R, Tseng H-T, Shan L, Fu L, Moore DD (2009) Circadian dysregulation disrupts bile acid homeostasis. PLoS One 4:e6843
    • View reference on publisher's website
    • View reference on PubMed
  32. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7:678–693
    • View reference on publisher's website
    • View reference on PubMed
  33. Houten SM, Watanabe M, Auwerx J (2006) Endocrine functions of bile acids. EMBO J 25:1419–1425
    • View reference on publisher's website
    • View reference on PubMed
  34. Schaap FG, Trauner M, Jansen PLM (2014) Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 11:55–67
    • View reference on publisher's website
    • View reference on PubMed
  35. de Aguiar Vallim TQ, Tarling EJ, Edwards PA (2013) Pleiotropic roles of bile acids in metabolism. Cell Metab 17:657–669
    • View reference on publisher's website
    • View reference on PubMed
  36. Keitel V, Kubitz R, Haussinger D (2008) Endocrine and paracrine role of bile acids. World J Gastroenterol 14:5620–5629
    • View reference on publisher's website
    • View reference on PubMed
  37. Hirata K, Ikeda S, Honma T, Mitaka T, Furuhata T, Katsuramaki T, Hata F, Mukaiya M (2001) Sepsis and cholestasis: basic findings in the sinusoid and bile canaliculus. J Hepatobiliary Pancreatic Surg 8:20–26
    • View reference on publisher's website
  38. Koskinas J, Gomatos IP, Tiniakos DG, Memos N, Boutsikou M, Garatzioti A, Archimandritis A, Betrosian A (2008) Liver histology in ICU patients dying from sepsis: a clinico-pathological study. World J Gastroenterol 14:1389–1393
    • View reference on publisher's website
    • View reference on PubMed
  39. Lysova NL, Gurevich LE, Trusov OA, Shchegolev AI, Mishnev OD (2001) Immunohistochemical characteristics of the liver in patients with peritonitis (early autopsy). Bull Exp Biol Med 132:1125–1129
    • View reference on publisher's website
    • View reference on PubMed
  40. Lefkowitch JH (1982) Bile ductular cholestasis: an ominous histopathologic sign related to sepsis and “cholangitis lenta”. Hum Pathol 13:19–24
    • View reference on publisher's website
    • View reference on PubMed
  41. Trauner M, Meier PJ, Boyer JL (1998) Molecular pathogenesis of cholestasis. New Engl J Med 339:1217–1227
    • View reference on publisher's website
    • View reference on PubMed
  42. Jaeger C, Mayer G, Henrich R, Gossner L, Rabenstein T, May A, Guenter E, Ell C (2006) Secondary sclerosing cholangitis after long-term treatment in an intensive care unit: clinical presentation, endoscopic findings, treatment, and follow-up. Endoscopy 38:730–734
    • View reference on publisher's website
    • View reference on PubMed
  43. Kulaksiz H, Heuberger D, Engler S, Stiehl A (2008) Poor outcome in progressive sclerosing cholangitis after septic shock. Endoscopy 40:214–218
    • View reference on publisher's website
    • View reference on PubMed
  44. Green RM, Beier D, Gollan JL (1996) Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 111:193–198
    • View reference on publisher's website
    • View reference on PubMed
  45. Vanwijngaerden YM, Wauters J, Langouche L, Vander Perre S, Liddle C, Coulter S, Vanderborght S, Roskams T, Wilmer A, Van den Berghe G, Mesotten D (2011) Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology 54:1741–1752
    • View reference on publisher's website
    • View reference on PubMed
  46. Andrejko KM, Raj NR, Kim PK, Cereda M, Deutschman CS (2008) IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters. Shock 29:490–496
    • View reference on PubMed
  47. Geier A, Dietrich CG, Voigt S, Ananthanarayanan M, Lammert F, Schmitz A, Trauner M, Wasmuth HE, Boraschi D, Balasubramaniyan N, Suchy FJ, Matern S, Gartung C (2005) Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol 289:G831–G841
    • View reference on publisher's website
    • View reference on PubMed
  48. Cherrington NJ, Slitt AL, Li N, Klaassen CD (2004) Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 32:734–741
    • View reference on publisher's website
    • View reference on PubMed
  49. Elferink MGL, Olinga P, Draaisma AL, Merema MT, Faber KN, Slooff MJH, Meijer DKF, Groothuis GMM (2004) LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am J Physiol Gastrointest Liver Physiol 287:G1008–G1016
    • View reference on publisher's website
    • View reference on PubMed
  50. Donner MG, Warskulat U, Saha N, Häussinger D (2004) Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS. Biol Chem 385:331–339
    • View reference on publisher's website
    • View reference on PubMed
  51. Vanwijngaerden Y-M, Langouche L, Derde S, Liddle C, Coulter S, Van den Berghe G, Mesotten D (2014) Impact of parenteral nutrition versus fasting on hepatic bile acid production and transport in a rabbit model of prolonged critical illness. Shock 41:48–54
    • View reference on publisher's website
    • View reference on PubMed
  52. Zimmerman TL, Thevananther S, Ghose R, Burns AR, Karpen SJ (2006) Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260. J Biol Chem 281:15434–15440
    • View reference on publisher's website
    • View reference on PubMed
  53. Geier A, Fickert P, Trauner M (2006) Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol 3:574–585
    • View reference on publisher's website
    • View reference on PubMed
  54. Whitehead MW, Hainsworth I, Kingham JG (2001) The causes of obvious jaundice in South West Wales: perceptions versus reality. Gut 48:409–413
    • View reference on publisher's website
    • View reference on PubMed
  55. Clements WD, Parks R, Erwin P, Halliday MI, Barr J, Rowlands BJ (1996) Role of the gut in the pathophysiology of extrahepatic biliary obstruction. Gut 39:587–593
    • View reference on publisher's website
    • View reference on PubMed
  56. te Boekhorst T, Urlus M, Doesburg W, Yap SH, Goris RJ (1988) Etiologic factors of jaundice in severely ill patients. A retrospective study in patients admitted to an intensive care unit with severe trauma or with septic intra-abdominal complications following surgery and without evidence of bile duct obstruction. J Hepatol 7:111–117
    • View reference on publisher's website
  57. Carter BA, Shulman RJ (2007) Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat Clin Pract Gastroenterol Hepatol 4:277–287
    • View reference on publisher's website
    • View reference on PubMed
  58. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, Van Cromphaut S, Ingels C, Meersseman P, Muller J, Vlasselaers D, Debaveye Y, Desmet L, Dubois J, Van Assche A, Vanderheyden S, Wilmer A, Van den Berghe G (2011) Early versus late parenteral nutrition in critically ill adults. New Engl J Med 365:506–517
    • View reference on publisher's website
    • View reference on PubMed
  59. Hermans G, Casaer MP, Clerckx B, Güiza F, Vanhullebusch T, Derde S, Meersseman P, Derese I, Mesotten D, Wouters PJ, Van Cromphaut S, Debaveye Y, Gosselink R, Gunst J, Wilmer A, Van den Berghe G, Vanhorebeek I (2013) Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. Lancet Respir Med 1:621–629
    • View reference on publisher's website
    • View reference on PubMed
  60. Vanwijngaerden Y-M, Langouche L, Brunner R, Debaveye Y, Gielen M, Casaer M, Liddle C, Coulter S, Wouters PJ, Wilmer A, Van den Berghe G, Mesotten D (2013) Withholding parenteral nutrition during critical illness increases plasma bilirubin but lowers the incidence of biliary sludge. Hepatology ;60:202–610
  61. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R (2006) Intensive insulin therapy in the medical ICU. New Engl J Med 354:449–461
    • View reference on publisher's website
    • View reference on PubMed
  62. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in critically ill patients. New Engl J Med 345:1359–1367
    • View reference on publisher's website
    • View reference on PubMed
  63. Gonnert FA, Recknagel P, Hilger I, Claus RA, Bauer M, Kortgen A (2013) Hepatic excretory function in sepsis: implications from biophotonic analysis of transcellular xenobiotic transport in a rodent model. Crit Care 17:R67
    • View reference on publisher's website
    • View reference on PubMed
  64. Recknagel P, Gonnert FA, Westermann M, Lambeck S, Lupp A, Rudiger A, Dyson A, Carré JE, Kortgen A, Krafft C, Popp J, Sponholz C, Fuhrmann V, Hilger I, Claus RA, Riedemann NC, Wetzker R, Singer M, Trauner M, Bauer M (2012) Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med 9:e1001338
    • View reference on publisher's website
    • View reference on PubMed
  65. Yang K, Köck K, Sedykh A, Tropsha A, Brouwer KLR (2013) An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J Pharm Sci 102:3037–3057
    • View reference on publisher's website
    • View reference on PubMed
  66. Lammert C, Bjornsson E, Niklasson A, Chalasani N (2010) Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 51:615–620
    • View reference on publisher's website
    • View reference on PubMed
  67. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Kihara Y, Chayama K, Noma K, Nakashima A, Tomiyama H, Takase B, Yamashina A, Higashi Y (2012) Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation 126:598–603
    • View reference on publisher's website
    • View reference on PubMed
  68. Castilho Á, Aveleira CA, Leal EC, Simões NF, Fernandes CR, Meirinhos RI, Baptista FI, Ambrósio AF (2012) Heme oxygenase-1 protects retinal endothelial cells against high glucose- and oxidative/nitrosative stress-induced toxicity. PLoS One 7:e42428
    • View reference on publisher's website
    • View reference on PubMed
  69. Baranano DE, Rao M, Ferris CD, Snyder SH (2002) Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 99:16093–16098
    • View reference on publisher's website
    • View reference on PubMed
  70. Wang WW, Smith DLH, Zucker SD (2004) Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology 40:424–433
    • View reference on publisher's website
    • View reference on PubMed
  71. Wiesel P, Patel AP, DiFonzo N, Marria PB, Sim CU, Pellacani A, Maemura K, LeBlanc BW, Marino K, Doerschuk CM, Yet SF, Lee ME, Perrella MA (2000) Endotoxin-induced mortality is related to increased oxidative stress and end-organ dysfunction, not refractory hypotension, in heme oxygenase-1-deficient mice. Circulation 102:3015–3022
    • View reference on publisher's website
    • View reference on PubMed
  72. McNeilly AD, Macfarlane DP, O’Flaherty E, Livingstone DE, Mitić T, McConnell KM, McKenzie SM, Davies E, Reynolds RM, Thiesson HC, Skøtt O, Walker BR, Andrew R (2010) Bile acids modulate glucocorticoid metabolism and the hypothalamic-pituitary-adrenal axis in obstructive jaundice. J Hepatol 52:705–711
    • View reference on publisher's website
    • View reference on PubMed
  73. Boonen E, Vervenne H, Meersseman P, Andrew R, Mortier L, Declercq PE, Vanwijngaerden YM, Spriet I, Wouters PJ, Vander Perre S, Langouche L, Vanhorebeek I, Walker BR, Van den Berghe G (2013) Reduced cortisol metabolism during critical illness. New Engl J Med 368:1477–1488
    • View reference on publisher's website
    • View reference on PubMed
  74. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484–489
    • View reference on publisher's website
    • View reference on PubMed
  75. Katsuma S, Hirasawa A, Tsujimoto G (2005) Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329:386–390
    • View reference on publisher's website
    • View reference on PubMed
  76. Alsatie M, Kwo PY, Gingerich JR, Qi R, Eckert G, Cummings OW, Imperiale TF (2007) A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C. J Clin Gastroenterol 41:416–421
    • View reference on publisher's website
    • View reference on PubMed
  77. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ (2007) Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28:940–946
    • View reference on publisher's website
    • View reference on PubMed
  78. Zhang Y, Xu P, Park K, Choi Y, Moore DD, Wang L (2008) Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 48:289–298
    • View reference on publisher's website
    • View reference on PubMed
  79. Lang E, Gatidis S, Freise NF, Bock H, Kubitz R, Lauermann C, Orth HM, Klindt C, Schuier M, Keitel V, Reich M, Liu G, Schmidt S, Xu HC, Qadri SM, Herebian D, Pandyra AA, Mayatepek E, Gulbins E, Lang F, Haussinger D, Lang KS, Foller M, Lang PA (2015) Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology 61:275–284
    • View reference on publisher's website
    • View reference on PubMed
  80. Yang LQ, Tao KM, Liu YT, Cheung CW, Irwin MG, Wong GT, Lv H, Song JG, Wu FX, Yu WF (2011) Remifentanil preconditioning reduces hepatic ischemia-reperfusion injury in rats via inducible nitric oxide synthase expression. Anesthesiology 114:1036–1047
    • View reference on publisher's website
    • View reference on PubMed
  81. Zhao G, Shen X, Nan H, Yan L, Zhao H, Yu J, Lv Y (2013) Remifentanil protects liver against ischemia/reperfusion injury through activation of anti-apoptotic pathways. J Surg Res 183:827–834
    • View reference on publisher's website
    • View reference on PubMed
  82. Beuers U (2006) Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3:318–328
    • View reference on publisher's website
    • View reference on PubMed
  83. Zimmerman JE, Kramer AA, McNair DS, Malila FM (2006) Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today’s critically ill patients. Crit Care Med 34:1297–1310
    • View reference on publisher's website
    • View reference on PubMed
  84. Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement